Effect of octreotide treatment on graves' ophthalmopathy

Endocrine Journal

Volumn 46, Issue 4, 1999, Pages 573-577

  Uysal, ALi Riza ^a   Çorapçioǧlu, Demet ^a,b   Tonyukuk, Vedia Cesur ^a   Güllü, Sevim ^a   Hasan, Sav ^a   Kamel, Nuri ^a   Erdoǧan, Gürbüz ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b Ibni Sina Hastanesi   (Turkey)

Author keywords

Graves' ophthalmopathy; Octreotide

Indexed keywords

OCTREOTIDE; PROPYLTHIOURACIL; THIAMAZOLE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EXOPHTHALMOS; FEMALE; FLATULENCE; GRAVES DISEASE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0344604464     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.46.573     Document Type: Article

References (14)

1. Özata M, Bolu E, Şengül A, Tasar M, Beyhan, Z, Çorakçi A, and Gündoǧan MA (1996) Effects of octreotide treatment of Graves ophthalmopathy and circulating sICAM - 1 levels. Thyroid 6: 283-288.
2. Chang TC, Kao SCS, Huang KM (1992) Octreotide and Graves' ophthalmopathy and pretibial myxedema. Br Med J 304: 158.
3. Krassas GE, Kaltsas Th, Dumas A, Pontikides N, Tolis G (1997) Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 136: 416-422.
4. Kung AWC, Michon J, Tai KS, Chan FL (1996) The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid 6: 381-384.
5. Khoo DHC, Tan YT, Fok, ACK, Tan CE (1995) Octreotide in the management of Grave's ophthalmopathy - changes in insulin - like growth factor 1 levels do not predict clinical response. Am J Clin Res 4: 33-42.
6. Durak I, Durak H, Ergin M, Yürekli Y, Kaynak S (1995) Somatostatin receptors in the orbits. Clin Nuclear Med 20: 237-242.
7. Erdoǧan G, Güllü S, Ilgin ŞŞ, Kamel AN, Başkal N, Uysal AR, Tonyukuk V, Çorapçioǧlu D (1998) Evaluation of the protrusion values of a healthy population with hertel exophthalmometer. J Ankara Med School 20: 135-137.
8. Wartofsky L (1992) Classification of eye changes of Graves' disease. Thyroid 2: 235-236.
9. Krassas GE, Dumas A, Pontikides N, Kaltsas Th (1995) Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol 42: 571-580.
10. Krassas GE (1998) Somatostatin analogues in the treatment of thyroid eye disease. Thyroid 8: 443-445.
11. 1] octreotide scintigraphy in thyroidal and orbital Graves' diseases. A parameter for disease activity. J Clin Endocrinol Metab 79: 1845-1851.
12. Kahaly G, Diaz M, Hahn K, Beyer J, Bockisch A (1995) Indium -111-Pentetreotide scintigraphy in Graves' ophthalmopathy. J Nucl Med 36: 550-554.
13. Chang TC, Ya WC, Chang CC (1992) Octreotide and urinary glycosaminoglycan in Graves' disease (letter). Br Med J 304: 1444.
14. Lamberts SWY, Oosterom R, Neufeld M, Del Pozo E (1985) The Somatostatin analog SMS 201-995 induces long - acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60: 1161-1165.